![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: NCL |
Gene summary for NCL |
![]() |
Gene information | Species | Human | Gene symbol | NCL | Gene ID | 4691 |
Gene name | nucleolin | |
Gene Alias | C23 | |
Cytomap | 2q37.1 | |
Gene Type | protein-coding | GO ID | GO:0000375 | UniProtAcc | A0A024R4A0 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
4691 | NCL | CA_HPV_1 | Human | Cervix | CC | 4.72e-16 | 6.24e-02 | 0.0264 |
4691 | NCL | CA_HPV_3 | Human | Cervix | CC | 1.94e-02 | 2.23e-01 | 0.0414 |
4691 | NCL | CCI_1 | Human | Cervix | CC | 1.52e-15 | -9.54e-01 | 0.528 |
4691 | NCL | CCI_3 | Human | Cervix | CC | 2.24e-02 | -4.02e-01 | 0.516 |
4691 | NCL | CCII_1 | Human | Cervix | CC | 2.21e-17 | -8.02e-01 | 0.3249 |
4691 | NCL | Tumor | Human | Cervix | CC | 1.33e-11 | -4.11e-01 | 0.1241 |
4691 | NCL | sample3 | Human | Cervix | CC | 5.01e-17 | -3.74e-01 | 0.1387 |
4691 | NCL | L1 | Human | Cervix | CC | 3.17e-10 | -5.94e-01 | 0.0802 |
4691 | NCL | T1 | Human | Cervix | CC | 4.68e-03 | -3.47e-01 | 0.0918 |
4691 | NCL | T3 | Human | Cervix | CC | 1.71e-15 | -3.70e-01 | 0.1389 |
4691 | NCL | HTA11_3410_2000001011 | Human | Colorectum | AD | 1.81e-06 | 2.44e-01 | 0.0155 |
4691 | NCL | HTA11_1938_2000001011 | Human | Colorectum | AD | 2.19e-09 | 6.93e-01 | -0.0811 |
4691 | NCL | HTA11_78_2000001011 | Human | Colorectum | AD | 3.71e-09 | 6.10e-01 | -0.1088 |
4691 | NCL | HTA11_347_2000001011 | Human | Colorectum | AD | 1.01e-22 | 8.11e-01 | -0.1954 |
4691 | NCL | HTA11_83_2000001011 | Human | Colorectum | SER | 1.63e-05 | 5.53e-01 | -0.1526 |
4691 | NCL | HTA11_696_2000001011 | Human | Colorectum | AD | 4.22e-09 | 5.12e-01 | -0.1464 |
4691 | NCL | HTA11_866_2000001011 | Human | Colorectum | AD | 1.96e-07 | 4.30e-01 | -0.1001 |
4691 | NCL | HTA11_1391_2000001011 | Human | Colorectum | AD | 4.45e-18 | 1.20e+00 | -0.059 |
4691 | NCL | HTA11_546_2000001011 | Human | Colorectum | AD | 3.76e-06 | 6.57e-01 | -0.0842 |
4691 | NCL | HTA11_7862_2000001011 | Human | Colorectum | AD | 1.71e-09 | 7.95e-01 | -0.0179 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004348410 | Cervix | CC | regulation of RNA splicing | 42/2311 | 148/18723 | 1.25e-07 | 6.24e-06 | 42 |
GO:19033119 | Cervix | CC | regulation of mRNA metabolic process | 64/2311 | 288/18723 | 1.71e-06 | 5.64e-05 | 64 |
GO:000641710 | Cervix | CC | regulation of translation | 89/2311 | 468/18723 | 1.86e-05 | 3.46e-04 | 89 |
GO:004802410 | Cervix | CC | regulation of mRNA splicing, via spliceosome | 28/2311 | 101/18723 | 2.41e-05 | 4.19e-04 | 28 |
GO:00713648 | Cervix | CC | cellular response to epidermal growth factor stimulus | 16/2311 | 45/18723 | 5.24e-05 | 7.83e-04 | 16 |
GO:00506849 | Cervix | CC | regulation of mRNA processing | 33/2311 | 137/18723 | 1.06e-04 | 1.35e-03 | 33 |
GO:00708498 | Cervix | CC | response to epidermal growth factor | 16/2311 | 49/18723 | 1.67e-04 | 1.99e-03 | 16 |
GO:19033136 | Cervix | CC | positive regulation of mRNA metabolic process | 29/2311 | 118/18723 | 1.86e-04 | 2.18e-03 | 29 |
GO:00331208 | Cervix | CC | positive regulation of RNA splicing | 13/2311 | 37/18723 | 2.99e-04 | 3.21e-03 | 13 |
GO:000838010 | Cervix | CC | RNA splicing | 76/2311 | 434/18723 | 9.79e-04 | 8.19e-03 | 76 |
GO:19908234 | Cervix | CC | response to leukemia inhibitory factor | 22/2311 | 95/18723 | 2.40e-03 | 1.70e-02 | 22 |
GO:19908304 | Cervix | CC | cellular response to leukemia inhibitory factor | 21/2311 | 94/18723 | 4.68e-03 | 2.82e-02 | 21 |
GO:000037710 | Cervix | CC | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 55/2311 | 320/18723 | 6.71e-03 | 3.70e-02 | 55 |
GO:000039810 | Cervix | CC | mRNA splicing, via spliceosome | 55/2311 | 320/18723 | 6.71e-03 | 3.70e-02 | 55 |
GO:000037510 | Cervix | CC | RNA splicing, via transesterification reactions | 55/2311 | 324/18723 | 8.61e-03 | 4.44e-02 | 55 |
GO:0008380 | Colorectum | AD | RNA splicing | 169/3918 | 434/18723 | 3.59e-18 | 2.04e-15 | 169 |
GO:0000377 | Colorectum | AD | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 130/3918 | 320/18723 | 5.88e-16 | 2.16e-13 | 130 |
GO:0000398 | Colorectum | AD | mRNA splicing, via spliceosome | 130/3918 | 320/18723 | 5.88e-16 | 2.16e-13 | 130 |
GO:0000375 | Colorectum | AD | RNA splicing, via transesterification reactions | 131/3918 | 324/18723 | 7.11e-16 | 2.22e-13 | 131 |
GO:1903311 | Colorectum | AD | regulation of mRNA metabolic process | 117/3918 | 288/18723 | 1.69e-14 | 4.23e-12 | 117 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0513020 | Cervix | CC | Pathogenic Escherichia coli infection | 63/1267 | 197/8465 | 9.28e-10 | 2.00e-08 | 1.19e-08 | 63 |
hsa05130110 | Cervix | CC | Pathogenic Escherichia coli infection | 63/1267 | 197/8465 | 9.28e-10 | 2.00e-08 | 1.19e-08 | 63 |
hsa05130 | Colorectum | AD | Pathogenic Escherichia coli infection | 79/2092 | 197/8465 | 1.05e-06 | 1.36e-05 | 8.65e-06 | 79 |
hsa051301 | Colorectum | AD | Pathogenic Escherichia coli infection | 79/2092 | 197/8465 | 1.05e-06 | 1.36e-05 | 8.65e-06 | 79 |
hsa051302 | Colorectum | SER | Pathogenic Escherichia coli infection | 60/1580 | 197/8465 | 3.63e-05 | 4.31e-04 | 3.13e-04 | 60 |
hsa051303 | Colorectum | SER | Pathogenic Escherichia coli infection | 60/1580 | 197/8465 | 3.63e-05 | 4.31e-04 | 3.13e-04 | 60 |
hsa051304 | Colorectum | MSS | Pathogenic Escherichia coli infection | 73/1875 | 197/8465 | 1.10e-06 | 1.48e-05 | 9.06e-06 | 73 |
hsa051305 | Colorectum | MSS | Pathogenic Escherichia coli infection | 73/1875 | 197/8465 | 1.10e-06 | 1.48e-05 | 9.06e-06 | 73 |
hsa051306 | Colorectum | MSI-H | Pathogenic Escherichia coli infection | 31/797 | 197/8465 | 2.90e-03 | 2.93e-02 | 2.46e-02 | 31 |
hsa051307 | Colorectum | MSI-H | Pathogenic Escherichia coli infection | 31/797 | 197/8465 | 2.90e-03 | 2.93e-02 | 2.46e-02 | 31 |
hsa051308 | Colorectum | FAP | Pathogenic Escherichia coli infection | 62/1404 | 197/8465 | 1.37e-07 | 3.08e-06 | 1.87e-06 | 62 |
hsa051309 | Colorectum | FAP | Pathogenic Escherichia coli infection | 62/1404 | 197/8465 | 1.37e-07 | 3.08e-06 | 1.87e-06 | 62 |
hsa0513010 | Colorectum | CRC | Pathogenic Escherichia coli infection | 47/1091 | 197/8465 | 1.49e-05 | 3.84e-04 | 2.60e-04 | 47 |
hsa0513011 | Colorectum | CRC | Pathogenic Escherichia coli infection | 47/1091 | 197/8465 | 1.49e-05 | 3.84e-04 | 2.60e-04 | 47 |
hsa0513026 | Endometrium | AEH | Pathogenic Escherichia coli infection | 50/1197 | 197/8465 | 1.72e-05 | 1.86e-04 | 1.36e-04 | 50 |
hsa05130112 | Endometrium | AEH | Pathogenic Escherichia coli infection | 50/1197 | 197/8465 | 1.72e-05 | 1.86e-04 | 1.36e-04 | 50 |
hsa0513027 | Endometrium | EEC | Pathogenic Escherichia coli infection | 51/1237 | 197/8465 | 1.98e-05 | 2.28e-04 | 1.70e-04 | 51 |
hsa0513036 | Endometrium | EEC | Pathogenic Escherichia coli infection | 51/1237 | 197/8465 | 1.98e-05 | 2.28e-04 | 1.70e-04 | 51 |
hsa05130211 | Esophagus | ESCC | Pathogenic Escherichia coli infection | 142/4205 | 197/8465 | 8.21e-11 | 1.06e-09 | 5.42e-10 | 142 |
hsa05130310 | Esophagus | ESCC | Pathogenic Escherichia coli infection | 142/4205 | 197/8465 | 8.21e-11 | 1.06e-09 | 5.42e-10 | 142 |
Page: 1 2 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
MDK | NCL | MDK_NCL | MK | Breast | ADJ |
MDK | NCL | MDK_NCL | MK | Breast | DCIS |
PTN | NCL | PTN_NCL | PTN | Breast | DCIS |
MDK | NCL | MDK_NCL | MK | Breast | Healthy |
PTN | NCL | PTN_NCL | PTN | Breast | Healthy |
MDK | NCL | MDK_NCL | MK | Breast | IDC |
MDK | NCL | MDK_NCL | MK | Breast | Precancer |
MDK | NCL | MDK_NCL | MK | Cervix | ADJ |
PTN | NCL | PTN_NCL | PTN | Cervix | ADJ |
MDK | NCL | MDK_NCL | MK | Cervix | CC |
PTN | NCL | PTN_NCL | PTN | Cervix | CC |
MDK | NCL | MDK_NCL | MK | Cervix | Healthy |
MDK | NCL | MDK_NCL | MK | Cervix | Precancer |
PTN | NCL | PTN_NCL | PTN | Cervix | Precancer |
MDK | NCL | MDK_NCL | MK | CRC | AD |
PTN | NCL | PTN_NCL | PTN | CRC | AD |
MDK | NCL | MDK_NCL | MK | CRC | ADJ |
MDK | NCL | MDK_NCL | MK | CRC | MSI-H |
MDK | NCL | MDK_NCL | MK | CRC | MSS |
MDK | NCL | MDK_NCL | MK | CRC | SER |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
NCL | SNV | Missense_Mutation | novel | c.1370G>A | p.Arg457Gln | p.R457Q | P19338 | protein_coding | deleterious(0.01) | probably_damaging(0.993) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
NCL | SNV | Missense_Mutation | novel | c.1946N>T | p.Gly649Val | p.G649V | P19338 | protein_coding | deleterious(0.03) | benign(0.258) | TCGA-DD-AAE4-01 | Liver | liver hepatocellular carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
NCL | SNV | Missense_Mutation | c.1321N>A | p.Asp441Asn | p.D441N | P19338 | protein_coding | tolerated(0.08) | benign(0.177) | TCGA-49-AARE-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
NCL | SNV | Missense_Mutation | novel | c.1410T>A | p.Asn470Lys | p.N470K | P19338 | protein_coding | tolerated(0.18) | benign(0.024) | TCGA-53-A4EZ-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Chemotherapy | cisplatin | CR |
NCL | SNV | Missense_Mutation | novel | c.736N>T | p.Asp246Tyr | p.D246Y | P19338 | protein_coding | deleterious(0) | possibly_damaging(0.525) | TCGA-55-A490-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Chemotherapy | carboplatin | SD |
NCL | SNV | Missense_Mutation | novel | c.499G>A | p.Glu167Lys | p.E167K | P19338 | protein_coding | deleterious_low_confidence(0.01) | benign(0.054) | TCGA-69-7978-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
NCL | SNV | Missense_Mutation | c.451N>A | p.Asp151Asn | p.D151N | P19338 | protein_coding | deleterious_low_confidence(0.02) | benign(0.052) | TCGA-86-8279-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Chemotherapy | etoposide | CR | |
NCL | SNV | Missense_Mutation | rs753488545 | c.1363G>A | p.Asp455Asn | p.D455N | P19338 | protein_coding | tolerated(0.07) | possibly_damaging(0.794) | TCGA-97-A4M3-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
NCL | SNV | Missense_Mutation | novel | c.1019A>G | p.Asp340Gly | p.D340G | P19338 | protein_coding | tolerated(0.09) | possibly_damaging(0.877) | TCGA-33-AASD-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
NCL | SNV | Missense_Mutation | novel | c.213G>T | p.Lys71Asn | p.K71N | P19338 | protein_coding | deleterious_low_confidence(0.01) | benign(0.014) | TCGA-52-7812-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Chemotherapy | paclitaxel | PD |
Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
4691 | NCL | NA | AS1411 | |||
4691 | NCL | NA | IPP-204106 | |||
4691 | NCL | NA | Itarnafloxin | QUARFLOXIN | 21455236 | |
4691 | NCL | NA | IPP-204106 | |||
4691 | NCL | NA | ACT-GRO-777 | 25057429 |
Page: 1 |